HIMS - NYSE
Hims & Hers Health, Inc.
$27.51
+3.5%Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
At a Glance
Live SnapshotHims & Hers Health, Inc. Management Team
Mr. Mike Chi
Chief Commercial Officer
Compensation
$1,109,963
Ms. Khobi Brooklyn
Chief Communications Officer
Mr. Oluyemi Okupe
Chief Financial Officer
Compensation
$1,192,044
Ms. Soleil Teubner Boughton J.D.
Chief Legal Officer & Corporate Secretary
Compensation
$986,951
Dr. Patrick Carroll M.D.
Chief Medical Officer & Director
Compensation
$44,000
Mr. Mike Chi
Chief Operating Officer & Chief Commercial Officer
Compensation
$1,109,963
Mr. Nader Kabbani
Chief Operations Officer
Mr. Mohamed ElShenawy
Chief Technology Officer
Mr. Andrew Dudum
Co-Founder, Chairman & Chief Executive Officer
Compensation
$1,900,915
Dr. Peter Stahl M.D.
Senior Vice President of Men's Reproductive & Sexual Health
Dr. Daniel Lieberman M.D.
Senior Vice President of Mental Health
Dr. Craig Primack M.D.
Senior Vice President of Weight Loss
Hims & Hers Health, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.17M and sold $79.24M worth of HIMS shares, resulting in $78.07M of net selling activity.
3 Months
48.4K
1.17M
212.8K
5.47M
-4.3M
-$4.30M
3-6 Months
0
0.00
92.9K
3.15M
-3.2M
-$3.15M
6-9 Months
0
0.00
321.6K
17.30M
-17.3M
-$17.30M
9-12 Months
0
0.00
1.0M
53.31M
-53.3M
-$53.31M
Top Buyers
Wells David B
Director
$1.17M
Top Sellers
Dudum Andrew
Director, 10 Percent Owner, Officer: Chief Executive Officer
$45.01M
Okupe Oluyemi
Officer: Chief Financial Officer
$17.51M
Chi Michael
Officer: Chief Operating Officer
$8.54M
Carroll Patrick Harrison
Director, Officer: Chief Medical Officer
$4.09M
Boughton Soleil
Officer: Chief Legal Officer
$2.36M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $78.07M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
HIMS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | May 17, 2021 | June 17, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.